Pipeline
Multi-module peptide programs across inflammation, barrier, and repair.
Our pipeline advances injectable, rationally engineered peptide candidates designed to engage the interconnected biology of atopic dermatitis — not a single cytokine axis.
KYN-001
Multi-module injectable peptide for AD (Module A + Module B)
Subcutaneous injectable
Preclinical
KYN-001 — Inflammation module
Resolution of inflammatory signaling
Peptide motif
Preclinical (clinically supported biology)
KYN-001 — β-defensin module
Barrier & antimicrobial support
β-defensin-derived motif
Preclinical — antimicrobial characterization ongoing
KYN-002
Multi-module injectable peptide for AD (Module A + B + C)
Subcutaneous injectable
Discovery / exploratory preclinical
KYN-002 — LRP1 module
Pro-repair / tissue signaling
LRP1-engaging motif
Exploratory / discovery
Half-life & formulation
Dosing interval & exposure optimization
Sequence / formulation strategies
Ongoing preclinical
KYN-001
Preclinical · Module A + Module B
Injectable peptide candidate for atopic dermatitis
KYN-001 is our lead program, designed to combine inflammation control with barrier-focused biology in a development-oriented format. It brings together an anti-inflammatory peptide module and a β-defensin-derived module to address two central dimensions of atopic dermatitis: dysregulated immune activity and impaired skin barrier defense.
KYN-002
Discovery / Exploratory · Module A + B + C
Next-generation multi-module injectable peptide
KYN-002 expands the KYN-001 framework by incorporating Module C, including an exploratory LRP1-engaging motif. This next-generation program is intended to extend the therapeutic concept beyond inflammation and barrier support toward a broader repair-oriented strategy.